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A bs tr ac t
Background
The role of coronary-artery bypass grafting (CABG) in the treatment of patients 
with coronary artery disease and heart failure has not been clearly established.
Methods
Between July 2002 and May 2007, a total of 1212 patients with an ejection fraction 
of 35% or less and coronary artery disease amenable to CABG were randomly as-
signed to medical therapy alone (602 patients) or medical therapy plus CABG (610 
patients). The primary outcome was the rate of death from any cause. Major second-
ary outcomes included the rates of death from cardiovascular causes and of death 
from any cause or hospitalization for cardiovascular causes.
Results
The primary outcome occurred in 244 patients (41%) in the medical-therapy group 
and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence 
interval [CI], 0.72 to 1.04; P = 0.12). A total of 201 patients (33%) in the medical-
therapy group and 168 (28%) in the CABG group died from an adjudicated cardio-
vascular cause (hazard ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death 
from any cause or hospitalization for cardiovascular causes occurred in 411 pa-
tients (68%) in the medical-therapy group and 351 (58%) in the CABG group (haz-
ard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P<0.001). By the end of the follow-
up period (median, 56 months), 100 patients in the medical-therapy group (17%) 
underwent CABG, and 555 patients in the CABG group (91%) underwent CABG.
Conclusions
In this randomized trial, there was no significant difference between medical ther-
apy alone and medical therapy plus CABG with respect to the primary end point of 
death from any cause. Patients assigned to CABG, as compared with those assigned 
to medical therapy alone, had lower rates of death from cardiovascular causes and 
of death from any cause or hospitalization for cardiovascular causes. (Funded by 
the National Heart, Lung, and Blood Institute and Abbott Laboratories; STICH 
ClinicalTrials.gov number, NCT00023595.)
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It is estimated that 5.8 million patients in the United States1 and 15 million in Europe2 have heart failure. Coronary artery disease is 
the most common substrate for heart failure in 
industrialized nations.3 However, the role of coro-
nary-artery bypass grafting (CABG) in the treat-
ment of patients with coronary artery disease and 
heart failure has not been clearly established.
In three landmark clinical trials in the 1970s, 
a total of 2234 patients with chronic stable an-
gina were randomly assigned to undergo CABG 
or receive medical therapy alone.4-6 The findings 
from these trials led to recommendations sup-
porting the use of CABG to relieve disabling 
symptoms of angina, particularly among high-
risk subgroups with extensive coronary artery 
disease.7,8 These trials excluded patients with 
severe left ventricular dysfunction (patients with 
an ejection fraction of <35%). A meta-analysis of 
the trials showed that 7.2% of the patients who 
underwent randomization had an ejection frac-
tion of 40% or less, and only 4.0% had primary 
symptoms of heart failure rather than angina.9 
Furthermore, these trials predate the major de-
velopments in medical therapy and cardiac sur-
gery that have led to the current guidelines.10-13 
More recently, observational analyses supporting 
a benefit of CABG14 and the proliferation of 
contemporary evidence-based medical and de-
vice-associated therapies have led to substantial 
clinical uncertainty regarding the incremental 
benefits of CABG relative to its risks in patients 
with ischemic cardiomyopathy.15,16
We designed the Surgical Treatment for Is-
chemic Heart Failure (STICH) trial to evaluate 
the role of cardiac surgery in the treatment of 
patients with coronary artery disease and left 
ventricular systolic dysfunction. A major hypoth-
esis of the trial was that CABG plus intensive 
medical therapy based on current guidelines, as 
compared with medical therapy alone, would 
reduce mortality.
Me thods
Study Design
The design of the STICH trial has been described 
previously.17,18 We conducted a multicenter, non-
blinded, randomized study at 127 clinical sites in 
26 countries. The trial protocol (available with 
the full text of this article at NEJM.org) was de-
signed by several of the authors and was ap-
proved by the principal investigator and the eth-
ics committee at each participating center. The 
trial was sponsored by the National Heart, Lung, 
and Blood Institute (NHLBI). Additional support 
was provided by Abbott Laboratories, which had 
no role in the conduct or reporting of the trial. 
An executive committee met weekly and moni-
tored the daily conduct of the trial. An indepen-
dent data and safety monitoring committee was 
appointed by the NHLBI. The Duke Clinical Re-
search Institute coordinated all aspects of global 
trial operations, site management and monitor-
ing, data collection, statistical analyses, and re-
porting. The authors reviewed the data, partici-
pated in the analyses and wrote the manuscript, 
and assume responsibility for the completeness 
and accuracy of the data and the analyses and for 
the fidelity of the study to the trial protocol.
Study Patients
Eligible patients had coronary artery disease that 
was amenable to CABG and an ejection fraction 
of 35% or less, as determined at each enrolling 
site. Details of the enrollment criteria are pro-
vided in Table 1 in the Supplementary Appendix, 
available at NEJM.org. All patients provided writ-
ten informed consent, as approved by the local 
institutional review board.
After initial determination of overall eligibil-
ity for the trial, patients were assessed to deter-
mine whether they were potential candidates for 
any of three possible therapeutic options: medi-
cal therapy alone, medical therapy plus CABG, 
or medical therapy plus CABG and surgical ven-
tricular reconstruction. Patients were eligible for 
medical therapy alone if they did not have a ste-
notic lesion leading to loss of 50% or more of 
the diameter of the left main coronary artery 
and if they did not have Canadian Cardiovascu-
lar Society class III or IV angina while receiving 
medical therapy. (The Canadian Cardiovascular 
Society angina classification ranges from class 0, 
which indicates no symptoms, to class IV, which 
indicates angina at any level of physical exertion.) 
Patients were eligible for surgical ventricular re-
construction if they had dominant anterior left 
ventricular akinesia or dyskinesia. As noted above, 
all patients were eligible for CABG.
On the basis of these eligibility criteria, pa-
tients were assigned by the enrolling physician to 
one of three trial strata. Stratum A included pa-
tients who were eligible for either medical therapy 
alone or medical therapy plus CABG, stratum B 
included patients who were eligible for any of the 
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three treatment options, and stratum C included 
patients who were eligible for either medical 
therapy plus CABG or medical therapy plus CABG 
and surgical ventricular reconstruction (Fig. 1 in 
the Supplementary Appendix). Patients were then 
randomly assigned to one of the treatment options 
for which they were eligible. As a result, all the 
patients in stratum A and some of the patients in 
stratum B were randomly assigned to either medi-
cal therapy alone or medical therapy plus CABG 
(the hypothesis 1 component of the STICH trial). 
All the patients in stratum C and some of the pa-
tients in stratum B were randomly assigned to ei-
ther medical therapy plus CABG or medical therapy 
plus CABG and surgical ventricular reconstruc-
tion (the hypothesis 2 component of the STICH 
trial). The results of the hypothesis 2 comparison 
have been reported previously.19 The results of the 
hypothesis 1 comparison are reported here.
Study Procedures
During the initial evaluation, information was ob-
tained on demographic factors and on clinical 
characteristics, including current medications and 
prior diagnostic and other cardiovascular proce-
dures, and a physical examination was performed. 
Patients were randomly assigned to medical ther-
apy alone or to medical therapy plus CABG by 
means of an investigator-initiated telephone call 
to an interactive voice-response system.
A lead cardiologist at each center was re-
sponsible for recommending the most appro-
priate medications and devices for the treat-
ment of heart failure and coronary artery disease 
on the basis of current guidelines. Adherence to 
treatment guidelines was emphasized in the 
care of all patients and was monitored by a 
medical therapy committee. Cardiac surgery was 
performed by surgeons who had provided data 
on at least 25 patients with an ejection fraction 
of 40% or less in whom they had performed 
CABG and among whom the operative death 
rate was 5% or less. CABG was to be performed 
within 14 days after randomization. A surgical 
therapy committee monitored the conduct of sur-
gery during the enrollment period. All patients 
underwent follow-up evaluations at the time of 
discharge or at 30 days, every 4 months for the 
first year, and every 6 months thereafter.
Study Outcomes
The primary outcome was the rate of death from 
any cause. Prespecified secondary outcomes in-
cluded the rate of death from cardiovascular 
causes and the rate of death from any cause or 
hospitalization for cardiovascular causes. The 
causes of death and of selected secondary out-
comes were adjudicated according to prespeci-
fied criteria by an independent clinical events 
committee whose members were unaware of the 
treatment assignments (see the definition of events 
in the Supplementary Appendix).
Statistical Analysis
We originally estimated that with a sample of 
2000 patients who would be followed for an aver-
age of approximately 3 years, the study would 
have 90% power to detect a 25% reduction in mor-
tality with CABG as compared with medical ther-
apy alone, assuming a 3-year mortality of 25% in 
the medical-therapy group. Because enrollment 
was slower than expected, we modified the design 
so that the sample size was reduced and the dura-
tion of the follow-up period was increased corre-
spondingly. The final study design specified that 
a sufficient number of patients had to be enrolled 
and the follow-up period had to be long enough 
that 400 deaths would occur; given this require-
ment, we estimated that we would need to enroll 
approximately 1200 patients, with an average fol-
low-up period of 5 years. These numbers allowed 
for as much as a 20% treatment crossover from 
medical therapy to CABG without reducing the 
study’s power to an unacceptable level. Random-
ization was performed with the use of permuted 
blocks and was stratified according to clinical site 
and stratum (A or B, as described above).
All major comparisons between the treatment 
groups were performed according to the inten-
tion-to-treat principle. Two-sided significance 
testing was used for all statistical tests. Cumula-
tive event rates were calculated according to the 
Kaplan–Meier method,20 with all event or censor-
ing times measured from the time of randomiza-
tion. The significance of differences in mortality 
between the treatment groups was assessed with 
the use of the log-rank test, with adjustment for 
randomization stratum. Relative risks were ex-
pressed as hazard ratios with associated confi-
dence intervals and were derived from the Cox 
proportional-hazards model.21,22 To characterize 
the time-dependent nature of the relative risks of 
the groups according to the treatment to which 
they had been randomly assigned, hazard ratios 
(and confidence intervals) were examined within 
time intervals of clinical importance: random-
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Table 1. Baseline Characteristics of the Patients.*
Variable
Medical Therapy
(N = 602)
CABG
(N = 610)
Age — yr
Median 59 60
Interquartile range 53–67 54–68
Female sex — no. (%) 75 (12) 73 (12)
Race or ethnic group — no. (%)†
White 402 (67) 389 (64)
Hispanic, Latino, or nonwhite 200 (33) 221 (36)
Body-mass index‡
Median 27 27
Interquartile range 24–30 24–30
Medical history — no. (%)
Previous myocardial infarction 472 (78) 462 (76)
Hyperlipidemia 370 (61) 360 (59)
Hypertension 370 (61) 358 (59)
Diabetes 238 (40) 240 (39)
Previous percutaneous coronary intervention 74 (12) 82 (13)
Chronic renal insufficiency 45 (7) 49 (8)
Previous stroke 41 (7) 51 (8)
Previous CABG 14 (2) 22 (4)
Current smoker 122 (20) 130 (21)
Current CCS angina class§
0 225 (37) 217 (36)
I 91 (15) 96 (16)
II 260 (43) 265 (43)
III 23 (4) 25 (4)
IV 3 (<1) 7 (1)
Current NYHA class
I 74 (12) 65 (11)
II 307 (51) 319 (52)
III 205 (34) 207 (34)
IV 16 (3) 19 (3)
Systolic blood pressure — mm Hg
Median 120 120
Interquartile range 110 –130 110 –130
Pulse — beats/min
Median 72 74
Interquartile range 65–80 66–82
6-Minute walk distance — ft¶
Median 1115 1145
Interquartile range 840–1345 863–1320
* CABG denotes coronary-artery bypass grafting, and NYHA New York Heart Association.
† Race or ethnic group was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The Canadian Cardiovascular Society (CCS) angina classification ranges from class 0, which indicates no symptoms, to 
class IV, which indicates angina at any level of physical exertion.
¶ To convert the values for the 6-minute walk distance to meters, multiply by 0.305.
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ization through 30 days, 31 through 365 days, 
366 days through 2 years, and any time after 2 
years. As prespecified in the study protocol, 
comparisons of the treatment groups were also 
performed with adjustment for key baseline fac-
tors (in addition to randomization stratum). The 
Cox model was also used to assess the consis-
tency of treatment effects by testing for interac-
tions between treatment and prespecified base-
line characteristics.
To aid in an assessment of the effect of treat-
ment crossovers, secondary as-treated and per-
protocol analyses were also performed. The as-
treated comparison was analyzed with the Cox 
model in which CABG was treated as a time-
dependent covariate.
Ten interim analyses of the data were per-
formed and were reviewed by the independent 
data and safety monitoring committee. Interim 
treatment comparisons for the primary outcome 
were monitored with the use of two-sided symmet-
ric O’Brien–Fleming boundaries generated with the 
Lan–DeMets alpha-spending-function approach 
to group-sequential testing.23,24 A significance 
level of 0.04 was required for the primary out-
come at the final analysis to adjust for the in-
terim analyses. The final clinical assessment for 
each patient was performed in the 4-month pe-
riod leading up to November 30, 2010, which was 
the cutoff date for analyses of all reported out-
comes.
R esult s
Study Population
Between July 24, 2002, and May 5, 2007, a total of 
2136 patients were enrolled in the overall STICH 
program; 1212 of these patients at 99 centers in 
22 countries were enrolled in the hypothesis 1 
component of the trial and were randomly as-
signed to receive medical therapy alone (602 pa-
tients) or medical therapy plus CABG (610 pa-
tients). Baseline demographic characteristics, 
clinical characteristics including details of ven-
tricular function and coronary anatomy, and med-
ication use were well balanced between the two 
groups (Table 1, and Tables 2 and 3 in the Supple-
mentary Appendix).
Table 2. Study Outcomes.*
Outcome
Medical 
Therapy
(N = 602)
CABG  
(N = 610)
Hazard Ratio 
with CABG
(95% CI) P Value†
no. (%)
Primary outcome: rate of death from any cause 244 (41) 218 (36) 0.86 (0.72–1.04) 0.12
Secondary outcomes
Death from any cause within 30 days after 
randomization
Logistic-regression model 7 (1) 22 (4) 3.19 (1.35–7.52)‡ 0.008
Cox proportional-hazards model 7 (1) 22 (4) 3.12 (1.33–7.31) 0.006
Death from cardiovascular causes 201 (33) 168 (28) 0.81 (0.66–1.00) 0.05
Death from any cause or hospitalization for 
heart  failure
324 (54) 290 (48) 0.84 (0.71–0.98) 0.03
Death from any cause or hospitalization for 
cardiovascular causes
411 (68) 351 (58) 0.74 (0.64–0.85) <0.001
Death from any cause or hospitalization for any cause 442 (73) 399 (65) 0.81 (0.71–0.93) 0.003
Death from any cause or revascularization with the 
use of PCI or CABG
333 (55) 237 (39) 0.60 (0.51–0.71) <0.001
* All analyses were adjusted for patient stratum (stratum A, which included patients eligible for either medical therapy 
alone or medical therapy plus CABG vs. stratum B, which included patients eligible for medical therapy alone, medical 
therapy plus CABG, or medical therapy plus CABG and surgical ventricular reconstruction). CABG denotes coronary- 
artery bypass grafting, and PCI percutaneous coronary intervention.
† All P values were calculated with the use of the log-rank test, except for one of the analyses of death from any cause 
within 30 days after randomization, for which, as noted, the P value was calculated with the use of the logistic-regres-
sion model.
‡ This value is an odds ratio rather than a hazard ratio.
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Study Treatments
Of the 610 patients randomly assigned to CABG, 
555 (91%) underwent CABG before the end of the 
study; the median time to the CABG procedure 
was 10 days (interquartile range, 5 to 16), with a 
maximum of 177 days. The surgery was performed 
electively in 529 of these patients (95%) and with 
urgency in 26 patients (5%). The median time in 
the intensive care unit was 52.4 hours (interquar-
tile range, 40.8 to 94.6), the median duration of 
intubation was 16.5 hours (interquartile range, 
11.1 to 22.4), and the median length of stay in the 
hospital was 9.0 days (interquartile range, 7.0 to 
13.0). A concurrent mitral-valve operation was per-
formed in 63 patients (11%). Of the 553 patients in 
the CABG group who underwent CABG and for 
whom data on arterial and venous conduits were 
available, 505 (91%) received at least one arterial 
conduit and 473 (86%) received one or more ve-
nous conduits. Overall, 484 patients (87%) in the 
CABG group who underwent CABG had two or 
more distal anastomoses placed during surgery.
Of the 602 patients randomly assigned to medi-
cal therapy alone, 100 (17%) underwent CABG 
before the end of the follow-up period. The me-
dian time to the CABG procedure was 142 days 
(interquartile range, 19 to 576), with a maximum 
of 2402 days. The most common indication for 
crossover to CABG was progressive symptoms 
(40%), followed by acute decompensation (27%), 
patient’s or family’s decision (28%), and physi-
cian’s decision (5%).
Adherence to guideline-based use of medica-
tions was high throughout the study period, with-
out significant differences between the treatment 
groups (Table 3 in the Supplementary Appendix). 
Postrandomization procedures are summarized in 
Table 4 in the Supplementary Appendix.
Follow-up
Final follow-up status was ascertained between 
August 1, 2010, and November 30, 2010, for 1207 
of the 1212 patients (99.6%) who underwent ran-
domization. During this last follow-up period, 
5 patients could not be evaluated; the median 
time from randomization to the date of the last 
contact for these 5 patients, which was the date 
on which follow-up data were censored, was 40 
months. The median length of follow-up was 56 
months (interquartile range, 48 to 68), with a 
minimum of 12 months and a maximum of 100 
months.
Outcomes
The primary outcome occurred in 244 of the 602 
patients (41%) assigned to medical therapy alone 
and in 218 of the 610 patients (36%) assigned to 
CABG (hazard ratio with CABG, 0.86; 95% confi-
dence interval [CI], 0.72 to 1.04; P = 0.12) (Table 2 
and Fig. 1). A total of 201 patients (33%) assigned 
to medical therapy and 168 (28%) assigned to 
CABG died from a cardiovascular cause (hazard 
ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; 
P = 0.05) (Table 2 and Fig. 2A). Death from any 
cause or hospitalization for cardiovascular causes 
occurred in 411 patients (68%) in the medical-
therapy group and 351 (58%) in the CABG group 
(hazard ratio with CABG, 0.74; 95% CI, 0.64 to 
0.85; P<0.001) (Table 2 and Fig. 2B). The results 
with respect to all other secondary clinical out-
comes also favored CABG, except for 30-day mor-
tality (Table 2). The results of models adjusted for 
covariates, including those with CABG as a time-
dependent covariate, are shown in Table 5 in the 
Supplementary Appendix.
We performed an as-treated analysis compar-
ing the 592 patients who were treated with 
medical therapy throughout the first year after 
randomization and the 620 patients who under-
went CABG either because they were randomly 
assigned to CABG or because they crossed over 
to CABG during year 1 of the follow-up period; 
the hazard ratio for the primary outcome with 
CABG was 0.70 (95% CI, 0.58 to 0.84; P<0.001) 
(Table 5 and Fig. 2 in the Supplementary Appen-
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Figure 1. Kaplan–Meier Curves for the Probability of Death from Any Cause.
CABG denotes coronary-artery bypass grafting.
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dix). We also performed a per-protocol compari-
son of the 537 patients randomly assigned to 
medical therapy who did not cross over to CABG 
during the first year of follow-up and the 555 
patients assigned to CABG who actually under-
went CABG; the hazard ratio for the primary 
outcome with CABG was 0.76 (95% CI, 0.62 to 
0.92; P = 0.005) (Table 5 and Fig. 3 in the Supple-
mentary Appendix).
Subgroup Analyses
There were no significant interactions between 
treatment assignment and baseline characteristics 
of interest with respect to the primary outcome, as 
shown in the hazard-ratio plots in Figure 3. A nom-
inally significant interaction with trial stratum was 
noted, but it is likely that this represents a chance 
finding.
Discussion
We compared the strategy of medical therapy alone 
with that of medical therapy plus CABG in patients 
with coronary artery disease and left ventricular 
dysfunction. The intention-to-treat analysis showed 
that there was no significant difference between 
the two trial groups with respect to the primary 
outcome, the rate of death from any cause. Between-
group differences in favor of CABG were seen with 
respect to the rate of death from cardiovascular 
causes and the rate of death from any cause or 
hospitalization for cardiovascular causes in the 
intention-to-treat analysis. The results of analyses 
performed according to whether patients actually 
underwent surgery, with and without adjustment 
for baseline variables, also favored CABG.
Although the randomization strategy specified 
in our statistical plan was adhered to, clinical 
circumstances led to crossover in the case of 17% 
of patients who had been randomly assigned to 
medical therapy and 9% who had been randomly 
assigned to CABG. Per-treatment analyses suggest 
that this imbalance in crossover rates between 
groups modified the results of the primary inten-
tion-to-treat analysis by diminishing the treat-
ment effect of CABG relative to medical therapy. 
Although we believe that these results are infor-
mative, since they mirror real-world clinical deci-
sion making, in which the choice of CABG is not 
influenced by randomization, these per-treatment 
analyses must be interpreted conservatively.
As anticipated, CABG was associated with an 
early risk of death from any cause among all pa-
tients who underwent the procedure. When pa-
tients are treated with CABG and intensive medical 
therapy for coronary artery disease and left ven-
tricular dysfunction, they are exposed to an early 
risk as a result of the surgical intervention. The 
total number of deaths was higher in the surgical 
group than in the medical-therapy group for more 
than 2 years after randomization.
Our study had several limitations. First, when 
the analysis in any trial fails to detect a signifi-
cant difference between treatment groups with 
respect to the primary outcome, analyses of sec-
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Figure 2. Kaplan–Meier Curves for the Probability of Death from Cardiovas-
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CABG denotes coronary-artery bypass grafting.
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ondary outcomes showing a benefit must inevi-
tably be considered to be somewhat provisional. 
Second, the between-group difference with re-
spect to death from cardiovascular causes, which 
is presumably the mortality outcome most likely 
to be influenced by CABG, had a P value of 0.05, 
which would not have been significant if it had 
been adjusted for multiple testing. Given the re-
All subjects
Age
≥65 yr
<65 yr
Sex
Male
Female
Race or ethnic group
Hispanic, Latino, or nonwhite
White
Region
Poland
United States
Canada
Western Europe
Other
Current NYHA class
I or II
III or IV
LVEF (best available)
≤27%
>27%
Stratum
A
B
Baseline diabetes
No
Yes
CCS angina class
0, I, or II
III or IV
No. of  vessels with ≥50% stenosis
1 or 2
3
≥50% Stenosis of LM or ≥75% stenosis of PLAD
No
Yes
Mitral regurgitation
None or trace
Mild (≤2+)
Moderate or severe (3+ or 4+)
No. of SubjectsSubgroup
P Value for
Interaction
1212
396
816
1064
148
421
791
319
120
123
87
563
765
447
612
600
1061
151
734
478
1154
58
478
733
373
838
435
554
220
0.41
0.61
0.09
0.39
0.83
0.20
0.01
0.56
0.30
0.23
0.40
0.59
0.50 1.00 2.00 4.00
Medical Therapy
Better
CABG
Better
Hazard Ratio (95% CI)
0.86 (0.72–1.04)
0.77 (0.59–1.01)
0.97 (0.69–1.36)
0.98 (0.73–1.32)
0.79 (0.62–0.99)
0.84 (0.70–1.01)
1.26 (0.57–2.79)
0.92 (0.70–1.22)
0.83 (0.65–1.05)
0.97 (0.73–1.29)
0.77 (0.60–0.98)
0.94 (0.78–1.15)
0.48 (0.28–0.81)
0.82 (0.66–1.02)
0.97 (0.69–1.35)
0.92 (0.63–1.35)
0.84 (0.63–1.12)
0.73 (0.54–0.97)
0.87 (0.69–1.11)
1.38 (0.77–2.47)
0.87 (0.48–1.60)
0.95 (0.68–1.33)
0.81 (0.47–1.40)
0.96 (0.77–1.19)
0.68 (0.49–0.95)
0.75 (0.42–1.31)
0.87 (0.72–1.06)
0.80 (0.63–1.01)
0.25
0.93 (0.70–1.23)
Figure 3. Hazard Ratio for Death from Any Cause, According to Subgroup.
Stratum A included patients eligible for either medical therapy alone or medical therapy plus coronary-artery bypass 
grafting (CABG), and stratum B included patients eligible for medical therapy alone, medical therapy plus CABG, or 
medical therapy plus CABG and surgical ventricular reconstruction. The Canadian Cardiovascular Society (CCS) an-
gina classification ranges from class 0, which indicates no symptoms, to class IV, which indicates angina at any level 
of physical exertion. LM denotes left main coronary artery, LVEF left ventricular ejection fraction, NYHA New York 
Heart Association, and PLAD proximal left anterior descending artery.
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sults of other secondary analyses, we believe that 
the lack of an unequivocally significant between-
group difference in the outcome of death from 
any given cause was more likely to have been 
due to limited power and limited duration of 
follow-up than to a true lack of benefit of CABG. 
Finally, since the trial was not blinded (and could 
not realistically have been blinded), the nonfatal 
outcomes (e.g., hospitalization due to various 
causes) could have been influenced by the clini-
cian’s knowledge of the treatment the patient 
received.
Clinical decision making for patients with 
coronary artery disease associated with left ven-
tricular dysfunction has been constrained by the 
absence of randomized, comparative data on re-
vascularization. In fact, small subgroup analyses 
of the previous randomized trials of CABG in-
volving patients with chronic stable angina dis-
suaded many clinicians from pursuing diagnostic 
assessments for coronary artery disease or revas-
cularization in patients presenting with heart 
failure.8,9 This approach continues to be sup-
ported by guidelines.10-13 In the absence of direct 
evidence, attention has shifted toward the detec-
tion of acutely and chronically underperfused but 
viable myocardium (i.e., myocardium that exhib-
its stunning or hibernation), a condition for 
which functional recovery may be achieved with 
reperfusion.25 Imaging strategies15,26 and clinical 
factors are routinely used to select patients who 
have the highest likelihood of functional recov-
ery, as well as those in whom CABG should be 
avoided. In another report in this issue of the 
Journal, STICH investigators provide additional 
information on the interaction between viable 
myocardium and treatment effect.27
In summary, the STICH trial compared medi-
cal therapy alone with medical therapy plus CABG 
in patients with coronary artery disease and left 
ventricular dysfunction. There was no significant 
difference between the two study groups with 
respect to the primary end point of the rate of 
death from any cause. The rates of death from 
cardiovascular causes and of death from any 
cause or hospitalization for cardiac causes were 
lower among patients assigned to CABG than 
among those assigned to medical therapy.
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